Key facts for NCD 190.15
- Benefit category
- Diagnostic Laboratory Tests
- Effective date
- 11/25/2002
- Implemented 01/01/2003
- Transmittal
- Transmittal 17
- Versions published
- 1
- Lab edit list
- Unlisted ICD-10 covered
- 22,258 listed codes not supported, 233 non-covered
TL;DR
NCD 190.15 sets Medicare's national policy for blood counts under the benefit category "Diagnostic Laboratory Tests", effective 11/25/2002 and implemented 01/01/2003. Indications for a CBC or hemogram include red cell, platelet, and white cell disorders. Examples of these indications are enumerated individually below. As a laboratory NCD it carries a national ICD-10 edit list that works by exclusion: any diagnosis code not on the list supports medical necessity, while 22,258 listed codes do not and 233 are denied, applied automatically by every Medicare contractor to 11 procedure codes.
Item or service described
Blood counts are used to evaluate and diagnose diseases relating to abnormalities of the blood or bone marrow. These include primary disorders such as anemia, leukemia, polycythemia, thrombocytosis and thrombocytopenia. Many other conditions secondarily affect the blood or bone marrow, including reaction to inflammation and infections, coagulopathies, neoplasms and exposure to toxic substances. Many treatments and therapies affect the blood or bone marrow, and blood counts may be used to monitor treatment effects.
The complete blood count (CBC) includes a hemogram and differential white blood count (WBC). The hemogram includes enumeration of red blood cells, white blood cells, and platelets, as well as the determination of hemoglobin, hematocrit, and indices.
The symptoms of hematological disorders are often nonspecific, and are commonly encountered in patients who may or may not prove to have a disorder of the blood or bone marrow. Furthermore, many medical conditions that are not primarily due to abnormalities of blood or bone marrow may have hematological manifestations that result from the disease or its treatment. As a result, the CBC is one of the most commonly indicated laboratory tests.
Inpatients with possible hematological abnormalities, it may be necessary to determine the hemoglobin and hematocrit, to calculate the red cell indices, and to measure the concentration of white blood cells and platelets. These measurements are usually performed on a multichannel analyzer that measures all of the parameters on every sample. Therefore, laboratory assessments routinely include these measurements.
Indications and limitations of coverage
Indications
Indications for a CBC or hemogram include red cell, platelet, and white cell disorders. Examples of these indications are enumerated individually below.
• Indications for a CBC generally include the evaluation of bone marrow dysfunction as a result of neoplasms, therapeutic agents, exposure to toxic substances, or pregnancy. The CBC is also useful in assessing peripheral destruction of blood cells, suspected bone marrow failure or bone marrow infiltrate, suspected myeloproliferative, myelodysplastic, or lymphoproliferative processes, and immune disorders.
• Indications for hemogram or CBC related to red cell (RBC) parameters of the hemogram include signs, symptoms, test results, illness, or disease that can be associated with anemia or other red blood cell disorder (e.g., pallor, weakness, fatigue, weight loss, bleeding, acute injury associated with blood loss or suspected blood loss, abnormal menstrual bleeding, hematuria, hematemesis, hematochezia, positive fecal occult blood test, malnutrition, vitamin deficiency, malabsorption, neuropathy, known malignancy, presence of acute or chronic disease that may have associated anemia, coagulation or hemostatic disorders, postural dizziness, syncope, abdominal pain, change in bowel habits, chronic marrow hypoplasia or decreased RBC production, tachycardia, systolic heart murmur, congestive heart failure, dyspnea, angina, nailbed deformities, growth retardation, jaundice, hepatomegaly, splenomegaly, lymphadenopathy, ulcers on the lower extremities).
• Indications for hemogram or CBC related to red cell (RBC) parameters of the hemogram include signs, symptoms, test results, illness, or disease that can be associated with polycythemia (for example, fever, chills, ruddy skin, conjunctival redness, cough, wheezing, cyanosis, clubbing of the fingers, orthopnea, heart murmur, headache, vague cognitive changes including memory changes, sleep apnea, weakness, pruritus, dizziness, excessive sweating, visual symptoms, weight loss, massive obesity, gastrointestinal bleeding, paresthesias, dyspnea, joint symptoms, epigastric distress, pain and erythema of the fingers or toes, venous or arterial thrombosis, thromboembolism, myocardial infarction, stroke, transient ischemic attacks, congenital heart disease, chronic obstructive pulmonary disease, increased erythropoietin production associated with neoplastic, renal or hepatic disorders, androgen or diuretic use, splenomegaly, hepatomegaly, diastolic hypertension.)
• Specific indications for CBC with differential count related to the WBC include signs, symptoms, test results, illness, or disease associated with leukemia, infections or inflammatory processes, suspected bone marrow failure or bone marrow infiltrate, suspected myeloproliferative, myelodysplastic or lymphoproliferative disorder, use of drugs that may cause leukopenia, and immune disorders (e.g., fever, chills, sweats, shock, fatigue, malaise, tachycardia, tachypnea, heart murmur, seizures, alterations of consciousness, meningismus, pain such as headache, abdominal pain, arthralgia, odynophagia, or dysuria, redness or swelling of skin, soft tissue bone, or joint, ulcers of the skin or mucous membranes, gangrene, mucous membrane discharge, bleeding, thrombosis, respiratory failure, pulmonary infiltrate, jaundice, diarrhea, vomiting, hepatomegaly, splenomegaly, lymphadenopathy, opportunistic infection such as oral candidiasis.)
• Specific indications for CBC related to the platelet count include signs, symptoms, test results, illness, or disease associated with increased or decreased platelet production and destruction, or platelet dysfunction(e.g., gastrointestinal bleeding, genitourinary tract bleeding, bilateral epistaxis, thrombosis, ecchymosis, purpura, jaundice, petechiae, fever, heparin therapy, suspected DIC, shock, pre-eclampsia, neonate with maternal ITP, massive transfusion, recent platelet transfusion, cardiopulmonary bypass, hemolytic uremic syndrome, renal diseases, lymphadenopathy, hepatomegaly, splenomegaly, hypersplenism, neurologic abnormalities, viral or other infection, myeloproliferative, myelodysplastic, or lymphoproliferative disorder, thrombosis, exposure to toxic agents, excessive alcohol ingestion, autoimmune disorders (SLE, RA and other).
• Indications for hemogram or CBC related to red cell (RBC) parameters of the hemogram include, in addition to those already listed, thalassemia, suspected hemoglobinopathy, lead poisoning, arsenic poisoning, and spherocytosis.
• Specific indications for CBC with differential count related to the WBC include, in addition to those already listed, storage diseases/mucopolysaccharidoses, and use of drugs that cause leukocytosis such as G-CSF or GM-CSF.
• Specific indications for CBC related to platelet count include, in addition to those already listed, May-Hegglin syndrome and Wiskott-Aldrich syndrome.
Limitations
• Testing of patients who are asymptomatic, or who do not have a condition that could be expected to result in a hematological abnormality, is screening and is not a covered service.
• In some circumstances it may be appropriate to perform only a hemoglobin or hematocrit to assess the oxygen carrying capacity of the blood. When the ordering provider requests only a hemoglobin or hematocrit, the remaining components of the CBC are not covered.
• When a blood count is performed for an end-stage renal disease (ESRD) patient, and is billed outside the ESRD rate, documentation of the medical necessity for the blood count must be submitted with the claim.
• In some patients presenting with certain signs, symptoms or diseases, a single CBC may be appropriate. Repeat testing may not be indicated unless abnormal results are found, or unless there is a change in clinical condition. If repeat testing is performed, a more descriptive diagnosis code (e.g., anemia) should be reported to support medical necessity. However, repeat testing may be indicated where results are normal in patients with conditions where there is a continued risk for the development of hematologic abnormality.
Note: Scroll down for links to the quarterly Covered Code Lists (including narrative).
Text reproduced from the CMS Medicare Coverage Database record for NCD 190.15 version 1. View the original on cms.gov.
Laboratory NCD code lists (October 2026)
Medicare contractors apply this NCD through a national edit: the procedure codes below are paid only when the claim carries a covered diagnosis. The October 2026 list works by exclusion: any ICD-10-CM code that is not on it supports medical necessity. It names 22,258 codes that do not support medical necessity and 233 non-covered codes that deny.
11 procedure codes are edited against this NCD's diagnosis list. CPT codes are shown as numbers only; descriptors are licensed by the AMA.
| Code | Code set |
|---|---|
| 85004 | CPT (descriptor licensed by AMA) |
| 85007 | CPT (descriptor licensed by AMA) |
| 85008 | CPT (descriptor licensed by AMA) |
| 85013 | CPT (descriptor licensed by AMA) |
| 85014 | CPT (descriptor licensed by AMA) |
| 85018 | CPT (descriptor licensed by AMA) |
| 85025 | CPT (descriptor licensed by AMA) |
| 85027 | CPT (descriptor licensed by AMA) |
| 85032 | CPT (descriptor licensed by AMA) |
| 85048 | CPT (descriptor licensed by AMA) |
| 85049 | CPT (descriptor licensed by AMA) |
What Medicare pays for these tests: 11 of the 11 codes carry a national payment amount on the October 2026 Clinical Laboratory Fee Schedule, from $2.37 to $7.77, with no deductible or coinsurance. QW marks the CLIA-waived variant of a test.
| Code | CLFS amount | With QW | Pricing |
|---|---|---|---|
| 85004 | $6.47 | — | national payment amount |
| 85007 | $3.80 | — | national payment amount |
| 85008 | $3.43 | — | national payment amount |
| 85013 | $7.00 | — | national payment amount |
| 85014 | $2.37 | $2.37 | national payment amount |
| 85018 | $2.37 | $2.37 | national payment amount |
| 85025 | $7.77 | $7.77 | national payment amount |
| 85027 | $6.47 | — | national payment amount |
| 85032 | $4.31 | — | national payment amount |
| 85048 | $2.54 | — | national payment amount |
| 85049 | $4.48 | — | national payment amount |
22,258 diagnosis codes on the list do not support medical necessity under this NCD; the first 20 are shown with FY2027 ICD-10-CM descriptions.
| ICD-10-CM | Description | Effective |
|---|---|---|
| A18.59 | Other tuberculosis of eye | 2015-10-01 |
| A63.0 | Anogenital (venereal) warts | 2015-10-01 |
| B07.0 | Plantar wart | 2015-10-01 |
| B07.8 | Other viral warts | 2015-10-01 |
| B07.9 | Viral wart, unspecified | 2015-10-01 |
| D00.00 | Carcinoma in situ of oral cavity, unspecified site | 2015-10-01 |
| D00.01 | Carcinoma in situ of labial mucosa and vermilion border | 2015-10-01 |
| D00.02 | Carcinoma in situ of buccal mucosa | 2015-10-01 |
| D00.03 | Carcinoma in situ of gingiva and edentulous alveolar ridge | 2015-10-01 |
| D00.04 | Carcinoma in situ of soft palate | 2015-10-01 |
| D00.05 | Carcinoma in situ of hard palate | 2015-10-01 |
| D00.06 | Carcinoma in situ of floor of mouth | 2015-10-01 |
| D00.07 | Carcinoma in situ of tongue | 2015-10-01 |
| D00.08 | Carcinoma in situ of pharynx | 2015-10-01 |
| D04.0 | Carcinoma in situ of skin of lip | 2015-10-01 |
| D04.10 | Carcinoma in situ of skin of unspecified eyelid, including canthus | 2015-10-01 |
| D04.111 | Carcinoma in situ of skin of right upper eyelid, including canthus | 2018-10-01 |
| D04.112 | Carcinoma in situ of skin of right lower eyelid, including canthus | 2018-10-01 |
| D04.121 | Carcinoma in situ of skin of left upper eyelid, including canthus | 2018-10-01 |
| D04.122 | Carcinoma in situ of skin of left lower eyelid, including canthus | 2018-10-01 |
233 diagnosis codes deny automatically under this NCD; the first 20 are shown.
| ICD-10-CM | Description |
|---|---|
| R99 | Ill-defined and unknown cause of mortality |
| Z00.00 | Encounter for general adult medical examination without abnormal findings |
| Z00.01 | Encounter for general adult medical examination with abnormal findings |
| Z00.110 | Health examination for newborn under 8 days old |
| Z00.111 | Health examination for newborn 8 to 28 days old |
| Z00.121 | Encounter for routine child health examination with abnormal findings |
| Z00.129 | Encounter for routine child health examination without abnormal findings |
| Z00.5 | Encounter for examination of potential donor of organ and tissue |
| Z00.6 | Encounter for examination for normal comparison and control in clinical research program |
| Z00.70 | Encounter for examination for period of delayed growth in childhood without abnormal findings |
| Z00.71 | Encounter for examination for period of delayed growth in childhood with abnormal findings |
| Z00.8 | Encounter for other general examination |
| Z02.0 | Encounter for examination for admission to educational institution |
| Z02.1 | Encounter for pre-employment examination |
| Z02.2 | Encounter for examination for admission to residential institution |
| Z02.3 | Encounter for examination for recruitment to armed forces |
| Z02.4 | Encounter for examination for driving license |
| Z02.5 | Encounter for examination for participation in sport |
| Z02.6 | Encounter for examination for insurance purposes |
| Z02.71 | Encounter for disability determination |
Changed in October 2026
The October 2026 lab NCD release changed this NCD's ICD-10-CM list: 3 codes added and 7 codes removed against January 2026. CMS marked 3 rows of the list as changed in this release. A removed code stops counting for the edit after its term date; where the FY2027 ICD-10-CM update deleted the code, the replacement codes listed below are the ones to report from October 1, 2026.
| ICD-10-CM | FY2027 description | Result |
|---|---|---|
| M72.20 | Plantar fascial fibromatosis, unspecified foot | does not support medical necessity |
| M72.21 | Plantar fascial fibromatosis, right foot | does not support medical necessity |
| M72.22 | Plantar fascial fibromatosis, left foot | does not support medical necessity |
| ICD-10-CM | Description | Was | Why |
|---|---|---|---|
| M72.2 | Plantar fascial fibromatosis | does not support medical necessity | deleted from ICD-10-CM; replaced by M67.A01, M67.A02, M67.A09, M72.20, M72.21, M72.22 |
| S23.420A | Sprain of sternoclavicular (joint) (ligament), initial encounter | does not support medical necessity | deleted from ICD-10-CM; replaced by no listed code |
| S23.420S | Sprain of sternoclavicular (joint) (ligament), sequela | does not support medical necessity | deleted from ICD-10-CM; replaced by no listed code |
| T52.8X1S | Toxic effect of other organic solvents, accidental (unintentional), sequela | does not support medical necessity | deleted from ICD-10-CM; replaced by T52.811S, T52.821S, T52.891S |
| T52.8X2S | Toxic effect of other organic solvents, intentional self-harm, sequela | does not support medical necessity | deleted from ICD-10-CM; replaced by T52.812S, T52.822S, T52.892S |
| T52.8X3S | Toxic effect of other organic solvents, assault, sequela | does not support medical necessity | deleted from ICD-10-CM; replaced by T52.813S, T52.823S, T52.893S |
| T52.8X4S | Toxic effect of other organic solvents, undetermined, sequela | does not support medical necessity | deleted from ICD-10-CM; replaced by T52.814S, T52.824S, T52.894S |
Codes on this NCD's list by release: October 2025: 22,394 · January 2026: 22,495 · October 2026: 22,491. Every change across the 23 laboratory NCDs is in the lab NCD code-list change report.
Revision history
12/2019 - Changes to the Laboratory National Coverage Determination (NCD) Edit Software for April 2020. This Change Request (CR) announces the changes that will be included in the April 2020 quarterly release of the edit module for clinical diagnostic laboratory services. This recurring update notification applies to chapter 16, section 120.2, publication 100-04. ( TN 4475 ) (CR11593)
07/2004 - Published NCD in the NCD Manual without change to narrative contained in PM AB-02-110. Coding guidance now published in Medicare Lab NCD Manual. Effective and Implementation dates NA. ( TN 17 ) (CR 2130)
07/2002 - Implemented NCD. Effective date 11/25/02. Implementation date 1/01/03. ( TN AB-02-110 ) (CR 2130)
How this NCD shows up on remittances
A service denied under a National Coverage Determination returns CARC 50 (not deemed medically necessary) with remark N386 (decision based on an NCD); a denial citing a local policy instead carries N115. Because NCDs bind nationally, the appeal path is documentation that the patient meets the indications above, not a contractor-policy argument.
For teams evaluating QuickIntell software
Evaluate a coverage-review workflow around NCD 190.15
Explore QuickAuth for requirement checks, documentation preparation and status tracking with staff oversight. Bring the policy-review steps your team repeats to a scoped evaluation, and confirm plan-specific requirements and supported actions. Use QuickRCM to evaluate the separate claim and denial workflow; a published NCD is not an authorization or payment guarantee.
Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.
Frequently asked questions — NCD 190.15
What does NCD 190.15 cover?
Indications for a CBC or hemogram include red cell, platelet, and white cell disorders. Examples of these indications are enumerated individually below. The full indications and limitations are reproduced on this page from the CMS Medicare Coverage Database.
When did NCD 190.15 take effect?
The current version (1) is effective 11/25/2002, implemented 01/01/2003, published in transmittal 17. This is the only published version.
Does a Local Coverage Determination override NCD 190.15?
No. A National Coverage Determination binds all Medicare Administrative Contractors; an LCD can only address services or circumstances the NCD leaves open. Claims denied under this NCD typically return CARC 50 with remark N386 (NCD) rather than N115 (LCD).
Which diagnosis codes are covered under NCD 190.15?
The October 2026 laboratory NCD edit list for blood counts works by exclusion: any ICD-10-CM code that is not on the list supports medical necessity. It lists 22,258 codes that do not support medical necessity (for example A18.59 Other tuberculosis of eye; A63.0 Anogenital (venereal) warts; B07.0 Plantar wart) and 233 codes that deny. The list applies to 85004, 85007, 85008, 85013, 85014, 85018 and others.
How often does the lab NCD code list for 190.15 change?
CMS updates the laboratory NCD edit module quarterly, with the October release carrying the annual ICD-10-CM code changes. Codes added or deleted mid-year appear in the quarterly change spreadsheets on the Lab NCDs page.
CMS guidance
Medicare Learning Network publications that CMS issues on this topic, cited by ICN and publication date:
- Complying With Documentation Requirements for Lab Services(MLN909221, )What documentation supports a laboratory claim: the order, the medical necessity and the results.
- Clinical Laboratory Fee Schedule(MLN006818, )How the Clinical Laboratory Fee Schedule is set, including data reporting and the payment determination.
Sources
Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.
- Medicare Coverage Database NCDs via the CMS Coverage APIVersion API snapshot 2026-09-27 · effective 2026-09-20 · file national-coverage-ncd.jsonSHA-256 a90fadfd264b9ef4…
- Laboratory NCD ICD-10 code lists, October 2026Version October 2026 · effective 2026-10-01 · file 2026400-Initial-ICD10-NCD-Spreadsheet-20260601-508.xlsxSHA-256 ec4361dc65f63432…
- ICD-10-CM FY2027 code descriptionsVersion FY2027 · effective 2026-10-01 · file icd10cm_codes_2027.txtSHA-256 3c0583a38ee0e848…
Disclaimer
This page reproduces the CMS National Coverage Determination text and, for laboratory NCDs, the CMS ICD-10 edit lists, as an operational reference. Coverage decisions depend on the full policy, the claim and the contractor; nothing here is legal, clinical or billing advice. CPT codes are shown as numbers only; CPT descriptors are copyright AMA.
Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.